Pliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on Monday

Pliant Therapeutics (NASDAQ:PLRX) is anticipated to issue its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Pliant Therapeutics Stock Performance

NASDAQ:PLRX opened at $1.30 on Friday. Pliant Therapeutics has a fifty-two week low of $1.09 and a fifty-two week high of $3.46. The company has a 50 day moving average price of $1.24 and a 200 day moving average price of $1.44. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.93 and a current ratio of 13.94. The stock has a market capitalization of $79.89 million, a P/E ratio of -0.45 and a beta of 1.38.

Wall Street Analysts Forecast Growth

PLRX has been the topic of several recent analyst reports. Wall Street Zen upgraded Pliant Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pliant Therapeutics in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, Pliant Therapeutics has a consensus rating of “Reduce” and an average price target of $3.92.

Insider Transactions at Pliant Therapeutics

In other Pliant Therapeutics news, CEO Bernard Coulie sold 89,375 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $1.28, for a total transaction of $114,400.00. Following the completion of the sale, the chief executive officer directly owned 505,601 shares in the company, valued at $647,169.28. This represents a 15.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 8.00% of the company’s stock.

Hedge Funds Weigh In On Pliant Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of PLRX. Tang Capital Management LLC increased its position in Pliant Therapeutics by 2.3% during the 4th quarter. Tang Capital Management LLC now owns 6,143,132 shares of the company’s stock worth $7,495,000 after purchasing an additional 139,686 shares in the last quarter. Woodline Partners LP lifted its position in Pliant Therapeutics by 91.8% during the third quarter. Woodline Partners LP now owns 4,504,817 shares of the company’s stock valued at $6,667,000 after buying an additional 2,156,291 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Pliant Therapeutics by 8.8% during the third quarter. JPMorgan Chase & Co. now owns 2,130,489 shares of the company’s stock worth $3,153,000 after buying an additional 172,056 shares during the period. Prosight Management LP grew its stake in Pliant Therapeutics by 7,493.8% during the fourth quarter. Prosight Management LP now owns 1,555,744 shares of the company’s stock worth $1,898,000 after buying an additional 1,535,257 shares during the period. Finally, Marshall Wace LLP increased its position in shares of Pliant Therapeutics by 260.7% in the fourth quarter. Marshall Wace LLP now owns 1,080,128 shares of the company’s stock worth $1,318,000 after acquiring an additional 780,667 shares in the last quarter. 97.30% of the stock is owned by institutional investors and hedge funds.

About Pliant Therapeutics

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).